Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heavy metal containing doai
Patent
1995-06-07
1998-01-13
Criares, Theodore J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heavy metal containing doai
A61K 3128
Patent
active
057080224
ABSTRACT:
Use of ruthenium complexes as immunosuppressive agents to prevent or significantly reduce graft rejection in organ and bone marrow transplantation is described. The ruthenium complexes can also be used as immunosuppressant drugs for T-lymphocyte mediated autoimmune diseases, such as diabetes, and may be useful in alleviating psoriasis and contact dermatitis. The ruthenium complexes can also be used therapeutically in the treatment of hyperproliferative vascular disease.
REFERENCES:
patent: 4843069 (1989-06-01), Keller et al.
patent: 5238689 (1993-08-01), Dwyer et al.
Bora et al., "Compounds of Imidazoles with Ruthenium (III) Chloride", Transition Met. Chem. 11:467-469 (1986).
Sundberg et al., "Nitrogen-Bound and Carbon-Bound Imidazole Complexes of Ruthenium Ammines", J. Amer. Chem. Soc., 96(2):381-92 (1974).
Sudha et al., "Electrochemical Evidence for a Two-Electron Reduction Process in a (.mu.-Oxo)bis(.mu.-acetato) diruthenium (III) Complex Containing Terminal 1-Methylimidazole Ligands", Inorganic Chem., 32:3801-3802 (1993).
Heijden et al., "Synthesis and Characterization of cis-(2,2'-Bipyridine) (2, 2'-biquinoline)dichlororuthenium (II) and its Co-ordination Chemistry with Imidazole Derivatives", J. Chem. Soc. Dalton Trans., 24:3675-9 (1993).
Krusyna et al., "Toxicology and Pharmacology of Some Ruthenium Compounds: Vascular Smooth Muscle Relaxtion by Nitrosyl Derivatives of Ruthenium and Iridium", J. Toxicol. Environ. Health, 6:757-773 (1980).
Grover et al., "Ruthenium Red Improves Postischemic Contractile Function in Isolated Rat Hearts", J. Cardiovasc. Pharmacol., 16(5):783-9 (1990).
Tanaka et al., "Inhibitors of Calcium-Dependent Cyclic Nucleotide Phosphodiesterase", Chemical Abstracts, 117(26): 25823, p. 457 (1992).
Tomiyama et al., "Beta-Adrenergic Blocking Action of Ruthenium Red", Japan J. Pharmacol., 23(6):889-91, (1973).
Anghileri, L., "The in vivo Inhibition of Tumor Growth by Ruthenium Red: Its Relationship with the Metabolism of Calcium in the Tumor", Z. Krebsforsch, 83:213-217 (1975).
Keppler et al., "Synthesis, Molecular Structure, and Tumor-Inhibiting Properties of Imidazolium trans-Bis(imidazole)tetrachlororuthenate(III) and Its Methyl-Substituted Derivatives", Inorg. Chem., 26(26):4366-4370 (1987).
Bastos Cecilia M.
Ocain Timothy D.
Criares Theodore J.
Procept Inc.
LandOfFree
Method for inhibiting immune response does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for inhibiting immune response, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for inhibiting immune response will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-326728